Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    Martinez-Velez N (1,2,3), Marigil M (1,2,3,4), García-Moure M (1,2,3), Gonzalez-Huarriz M (1,2,3), Aristu JJ (1,5), Ramos-García LI (5), Tejada S (1,2,6), Díez-Valle R (1,2,6), Patiño-García A (1,2,3), Becher OJ (7), Gomez-Manzano C (8,9), Fueyo J (8,10), Alonso MM (11,12,13).

    (1) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.
    (4) Division of Neurosurgery, Lariboisière University Hospital, 2 Rue Ambroise Paré, 75475, Paris, cedex 10, France.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (7) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (8) Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (9) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (10) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (11) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (12) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (13) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.

    Acta Neuropathologica Communications 29 de ABRIL de 2019

  • Rescuing Spanish Radiation Therapy: The Role of Leadership and Opportunity

    Lara PC (1), Rodríguez A (2), Ferrer C (3), Aristu JJ (4), Prada PJ (5), Muñoz J (6), Arenas M (7), Perez-Montero H (8)

    (1) Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas Gran Canaria, Spain.
    (2) Radiation Oncology Department, Hospital Ruber Internacional, Madrid, Spain.
    (3) Radiation Oncology Department, Complejo Hospitalario de Castellón, Castellón, Spain.
    (4) Radiation Oncology Department, Clínica Universitaria de Navarra, Pamplona, Spain.
    (5) Radiation Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
    (6) Radiation Oncology Department, Hospital Universitario Infanta Cristina, Badajoz, Spain.
    (7) Radiation Oncology Department, Hospital Universitario Sant Joan, Reus, Spain.
    (8) Radiation Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

    International Journal Radiation Oncology, Biology, Physics 01 de FEBRERO de 2018

  • A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    Inogés S (1,2), Tejada S (3), de Cerio AL (4,5), Pérez-Larraya JG (6), Espinós J (7), Idoate MA (8), Domínguez PD (9), de Eulate RG (9), Aristu J (10), Bendandi M (11,12), Pastor F (13), Alonso M (14), Andreu E (5), Cardoso FP (4,15), Valle RD (16). (1) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (2) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (3) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (4) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (5) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (6) Neurology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (7) Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (8) Pathology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (9) Radiology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (10) Radiation Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (11) Section on Hematology/Oncology, Department of Internal Medicine, Comprehensive Cancer Center, Wake Forest University Baptist Healthcare Center, Winston-Salem, NC, USA.
    (12) Section of Hematology/Oncology, Department of Internal Medicine, W.G Hefner VA Medical Center, Salisbury/Charlotte, NC, USA.
    (13) Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (14) Program in Solid Tumors and Biomarkers, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (15) Haematology and Haemotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (16) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain

    Journal of Transational Medicine 12 de MAYO de 2017

  • Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer

    Olarte A (1), Cambeiro M (1), Moreno-Jiménez M (2), Arbea L (1), Pérez-Gracia JL (3), Gil-Bazo I (3), Pascual I (4), Aristu J (1), Martínez-Monge R (5).
    (1) Department of Radiation Oncology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Navarre, Spain.
    (2) Department of Radiation Oncology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Navarre, Spain; Instituto de Investigación Biosanitaria de Navarra (IdiSNA), Pamplona, Navarre, Spain.
    (3) Department of Medical Oncology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Navarre, Spain.
    (4) Department of Urology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Navarre, Spain.
    (5) Department of Radiation Oncology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Navarre, Spain. 

    Brachytherapy 29 de ENERO de 2016

  • Influence of different treatment techniques and clinical factors over the intrafraction variation on lung stereotactic body radiotherapy

    Rico M (1), Martínez E (2), Pellejero S (3), Bermejo B (4), Navarrete P (2), Barrado M (2), Campo M (2), Mañeru F (3), Villafranca E (2), Aristu J (5).
    (1) Department of Radiation Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain. 
    (2) Department of Radiation Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (3) Department of Radiation Physics, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (4) Department of Preventive Medicine, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.

    Clinical & Translational Oncology 12 de ENERO de 2016

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra